Tranexamic
acid, HDFN, racial thresholds for transfusion… I learned a few things here. And
that’s what CPD is all about…
Safety and Effectiveness of Tranexamic Acid in Cardiac Surgery Patients
 | | August 10, 2022 | | Tranexamic
acid is an antifibrinolytic agent that is commonly used to control
bleeding in patients undergoing cardiac surgery. Limited randomized
controlled trial data, however, are available to determine the optimal
dose. High doses of tranexamic acid have been associated with seizures
and thrombotic events. [Read More] |
|
 | | In
this new Transfusion Science Webinar, Carla Dinardo, MD, PhD, explains
why the Hemolytic Disease of the Fetus and Newborn remains a challenge
despite the many advances made to either prevent, or diagnose and treat
HDFN and its complications. [Register Now] |
|
 | | August 3, 2022 | | Transfusion
guidelines recommend transfusing red blood cells (RBCs) when hemoglobin
(Hb) levels drop below 7 or 8 g/dL, but variation in transfusion
practices remain. In order to better understand racial differences in
transfusions in hospitalized general medicine patients with anemia [Read More] |
|
 | | July 27, 2022 | | Hypocalcemia
(Ca++ <1.1 mmol/L) has recently been identified as a fourth
component of the “lethal triad” for mortality of adult trauma patients
in addition to coagulopathy, acidosis, and hypothermia. Severe
hypocalcemia (Ca++ <1.0 mmol/L) is common, occurring in about a
quarter to half of all severely injured adult patients. [Read More] |
|
No comments:
Post a Comment